SpectraCure AB
The answer first
Does SpectraCure beat the market?
No, SpectraCure has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 27% of Nordic stocks
- Quality58
- Value58
- Trend1
No. 113 of 195 in healthcare
Max for seven days
Follow SpectraCure with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about SpectraCure
Your first answer is free, no account needed.
Do you own SpectraCure, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with SpectraCure and a few more. Free, no card.
Super Stock+44.6%In short
- SpectraCure has fallen 90.6% over the past year, including dividends.
- Overall, SpectraCure ranks better than 27% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 99.3%. The price is 99.9% below its peak now.
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 27% of Nordic stocks.
No. 113 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 113 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.13
- Asset turnoverSales divided by everything the company owns0.00
- Return on equityProfit divided by equity−59.3%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Medium Fair price: about the same as a typical Nordic stock.
No. 34 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity0.1
- P/SPrice divided by sales39.0
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 193 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−67.7%
- 6 months−82.2%
- 9 months−83.8%
- 12 months−90.6%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own SpectraCure
One fund we follow owns SpectraCure. The share is how much of the fund the stock makes up.
- Sweden1
From the funds' latest known holdings.
About SpectraCure
SpectraCure AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 13 employees.
SpectraCure AB (publ) engages in the development of cancer treatment system in Sweden. It develops Q-PRO, a laser unit; IDOSE software platform, which calculates the optimal laser light dose and placement of the optical fibers; and disposable items comprising needles, optical fibers, and light-sensitive medication. The company was incorporated in 2003 and is based in Lund, Sweden.


See the full analysis of SpectraCure.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card